Q & A Webcasts

Please click on a question to view webcast:

 
Speaker: Robert S. Brown, Jr., MD, MPH
1 How to treat relapsers to sofosbuvir containing regimen?
2 Should patients with HCV be treated prior to liver transplantation or wait until they are transplanted?
3 Should I treat my advanced cirrhotics? Is it safe and do I condemn them to meld purgatory if it works?
4 If a patient is detectable at week 4, should we extend treatment longer than what was originally approved?
5 Should patients with a viral load of 5 million IU/ml be treated with an 8 week regimen of sofosbuvir/ledipasvir? Does the presence of bridging fibrosis impact your treatment duration in this population?
6 How do you determine what regimen you will prescribe to which patient?
 
 
Speaker: Douglas Dieterich, MD
1 Should one treat G3 SOF+RBV failure patients with DCA+SOF and for how long, 12 weeks or 24 weeks and with or without RBV or wait for newer therapies?
2 How long would you treat a patient with genotype 1 and bridging fibrosis?
3 What do you do when you prescribe one HCV treatment and the insurance carrier approves the other?
4 When do you treat patients who are listed for liver transplant? And post transplantation?
5 Where do you see a role for ribavirin in the treatment of patients with HCV?
6 What is the role of HCV resistance testing?
 
 
Speaker: Ira Jacobson, MD
1 For genotype 1 cirrhotic patient with sofosbuvir/ledipasvir treatment failure, what is the next step. What are the options?
2 Management of sofosbuvir/ledipasvir relapser?
 
 
Speaker: Hillel Tobias, MD
1 What is a genotype and why is it important?
2 Do we need to treat everyone or can we wait?
3 What is the treatment for patients with decompensated cirrhosis (ascites, jaundice, hepatic encephalopathy) and is there the possibility of reversing decompensation with SVR? Are there any therapies we should avoid in these patients?
4 On the other extreme, what is the treatment for patients with minimal fibrosis and asymptomatic chronic hepatitis C? Please comment on genotypes 1 through 4.
5 Which antivirals can we use in patients with renal insufficiency?
6 Is it better to treat the listed patient’s HCV before or after transplant?
 
 

Target Audience - The educational initiative is intended for physicians, allied professionals, residents, fellows, and students from the specialties that we anticipate will be screening for, referring, and treating HCV and liver disease.

Statement of Need - The purpose of the activity to provide strategies to prevent disease, educate health care providers about the disease, increase disease surveillance, and improve the therapeutic management and patient outcomes.

Disclosure of Conflicts of Interest
Dr. Robert Brown is a Consultant/Advisor and has received research grant support from AbbVie, Genentech, Gilead, Janssen and Vertex.

Dr. Douglas Dieterich has received grant/research support from AbbVie, Gilead and Merck. Dr. Dieterich is a Consultant/Advisor for AbbVie, Gilead and Merck. He has received compensation for consulting fees and as an advisory board member from Achillion, Bristol-Myers Squibb and Janssen.

Dr. Ira Jacobson is a a speaker bureau member for AbbVie, Bristol Myers Squibb, Gilead and Janssen. He has received grant/research support from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Tobira. He is a consultant/advisor for AbbVie, Achillion, Alnylam, Bristol-Myers Squibb, Enanta, Gilead, Janssen and Merck.

Dr. Hillel Tobias, MD is a consultant/advisor for Bristol-Myers Squibb and Gilead. Dr Tobias has received honoraria for lectures, papers or teaching from Bristol-Myers Squibb and Gilead. Dr. Tobias has received compensation for service on advisory boards from Bristol-Myers Squibb and Gilead. Dr. Tobias has received consulting fees from Bristol-Myers Squibb and Gilead.

Medium There are no fees for participating in or receiving credit for this online activity.

Hardware/software requirements Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

Privacy and Confidentiality Policy The Icahn School of Medicine protects the privacy of personal and other information regarding participants and educational collaborations. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

Disclaimer – The information provided in this webcast is for continuing education purposes only. The content is not meant to provide medical judgment, diagnostic or treatment options for any medical condition. Use of this information is not suitable outside the scope of this activity.

Contact Information: For technical assistance, contact info@focusmeded.com.

Copyright - This material is protected by copyright and other intellectual property laws. It may not be otherwise copied, printed, transmitted, or published unless explicit permission is obtained. To request permission, please contact us at info@focusmeded.com.

Commercial Support - This activity is supported from independent educational grants from AbbVie, Bristol-Myers Squibb, Gilead, Janssen Therapeutics and Merck.